Paloma Partners’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Paloma Partners’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-68,678	Closed	-$60K	–	2439
2019 Q2	$60K	Buy	+68,678	New	+$108K	﹤0.01%	1651
2019 Q1	–	Sell	-12,000	Closed	-$28K	–	2072
2018 Q4	$28K	Buy	+12,000	New	+$106K	﹤0.01%	1187

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Paloma Partners's SNNA Position: Q3 2019 in Review

Paloma Partners sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 68,678 shares — an estimated $60K sold.

Paloma Partners first reported a position in SNNA in Q4 2018 and held it in 2 quarters. The position peaked at $60K in Q2 2019. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Paloma Partners reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 68,678 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $60K.
Paloma Partners first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
Paloma Partners's Sienna Biopharmaceuticals, Inc. position peaked at $60K in Q2 2019.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.